REMIX: Early CSU Symptom Improvement Observed with Remibrutinib Therapy

Remibrutinib treatment of chronic spontaneous urticaria (CSU) leads to fast, early symptom control versus placebo, according to new post-hoc analysis data presented at the 2026 American Academy of Dermatology (AAD) Annual Meeting in Denver.1

CSU is a chronic, idiopathic condition characterized by the recurrence of hives, pruritus, angioedema, or a combination of such symptoms lasting longer than 6 weeks.2,3 The condition is known to disproportionately impact women, and this is especially the case among those between 20 - 40 years of age. CSU is linked with a substantial burden, as beyond its physical manifestations, the disease has significant psychological and economic implications. The annual healthcare-related costs of CSU in the US exceed $200 million.

Remibrutinib is an oral, highly selective Bruton's tyrosine kinase (BTK) inhibitor, and had previously demonstrated efficacy and a positive safety profile in previous phase 2b data.2 During the latest phase 3 REMIX-1 and REMIX-2 trials, which are identical, multicenter, randomized, double-blind, placebo-controlled studies, remibrutinib was administered as an add-on therapy for patients whose symptoms persisted despite second-generation H1-antihistamines.

In these new data, the drug showed superior efficacy compared with placebo at the 12-week mark. The therapy has since been approved in both the US and China. In the current post-hoc analysis pooled data from the REMIX-1 and REMIX-2 trials, presented during AAD 2026, the investigative team set out to better understand how quickly patients begin to experience CSU symptom improvement after beginning remibrutinib treatment.

The team focused on daily hive severity scores (HSS) and itch severity scores (ISS), seeking to assess both mean shifts in scores over time and the proportion of individuals in the studies attaining complete resolution of their CSU symptoms (defined as HSS = 0 for no hives and ISS = 0 for no itch) from baseline through the first 7 days of therapy use.

They calculated both HSS and ISS via averaged morning and evening assessments, with the exception of the first day. This was when only the post-dose evening measurement, taken 12 hours after dosing, was included due to pre-dose morning values. Scoring of CSU severity ranged from 0 - 3, with higher scores suggesting a greater level of symptom burden.

Overall, the investigators’ pooled post-hoc data showed remibrutinib implementation led to a rapid reduction in CSU disease activity, with the investigators noting measurable improvements in both itch and hive severity within the first 12 hours following the initial remibrutinib dose. This early onset of action was notably faster than what was observed in the placebo arm. Additionally, the team found a higher proportion of those on remibrutinib attained complete resolution of symptoms within this same 12-hour timeframe.

The benefits persisted over the initial week of treatment. Across days 1 - 7, participants treated with remibrutinib consistently showed greater rates of complete CSU symptom control compared with subjects in the placebo arm. The proportion of those reaching HSS = 0 and ISS = 0 remained higher in the treatment cohort throughout this early treatment period.

Safety results from the pooled analysis were also described as consistent with previous reports from the REMIX program. Remibrutinib was generally well-tolerated, with a lack of new safety concerns being identified.

Overall, these data reinforce earlier findings from the phase 3 research, highlighting not only the efficacy and safety of remibrutinib but also its rapid onset of action. The drug’s ability to attain early symptom control may be particularly meaningful for those with CSU who continue to experience significant burden despite standard antihistamine use.

References

1. Early symptom improvement with remibrutinib in chronic spontaneous urticaria: Daily Itch Severity Scores and Hives Severity Scores from phase 3 REMIX-1/-2 studies. Poster presented at: 2026 American Academy of Dermatology Annual Meeting; March 27–31, 2026; Denver, CO. Poster DV-018384.

2. Metz M, Giménez-Arnau A, Maurer M, et al. Remibrutinib in Chronic Spontaneous Urticaria. N Engl J Med. 2025 Mar 6;392(10):984-994. doi: 10.1056/NEJMoa2408792. PMID: 40043237.

3. Tbakhi B, Ware K, Bernstein JA, et al. An Overview of Chronic Spontaneous Urticaria: Diagnosis, Management, and Treatment. Allergy Asthma Immunol Res. 2025 Sep;17(5):531-546. doi: 10.4168/aair.2025.17.5.531. PMID: 41044830; PMCID: PMC12511800.